Zetagen Therapeutics has filed a notice of an exempt offering of securities to raise $6,173,828.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Zetagen Therapeutics is raising up to $6,173,828.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Zetagen Therapeutics
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet, the Companys pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable and ancillary osteologic treatments including, ZetaFuse, ZetaSet, ZetaDent and ZetaBase. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.
To learn more about Zetagen Therapeutics, visit http://www.zetagen.com/
Zetagen Therapeutics Linkedin Page: https://www.linkedin.com/company/zetagen-therapeutics/
Contact:
Joe Loy, Chief Executive Officer
401-699-9402
https://www.linkedin.com/in/joe-loy-09160333/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.